Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814843 | 0.89 | USP2 (0.36) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL3815717 | 0.86 | USP2 (0.38) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL4755062 | 0.85 | USP2 (0.37) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL4757195 | 0.83 | CYP1A2 (0.32) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL3818174 | 0.83 | USP2 (0.32) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL5319912 | 0.82 | USP2 (0.35) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL3819378 | 0.82 | CYP1A2 (0.31) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL5148275 | 0.82 | CYP1A2 (0.31) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL4755074 | 0.81 | ALDH1A1 (0.31) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL5991169 | 0.77 | NAAA (0.37) | ALDH1A1USP2LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007027477-A2 | TREATING VULVODYNIA USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2008157408-A2 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1677812-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005027850-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |